Recent News
Read ArticleDay two at EULAR 2026 was jammed with sessions on advances in immune checkpoint inhhbitors (and irAEs), Lupus, Scleroderma, RA and IgG4 related disease. Here are a few of my favorites from Day 2.
5 years since Patient ID001: Progress on CAR-T Therapy in RMD
Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?
Read Article
EULAR 2026 Final Recap LIVE
The meeting may be ending, but the conversation is just beginning.
Join Dr. Jack Cush and https://t.co/V10S4oVFsv faculty for the final EULAR 2026 recap as they review the most important takeaways from Day 4 and identify the discoveries most likely https://t.co/00WnCx4FLt
Links:
Dr. John Cush @RheumNow ( View Tweet)
Emapalumab in MAS secondary to stills disease
39 pts, median age 12, 2 pooled prospective, open label, single arm studies.
Endpoint complete resolution at week 8-. Around 60% and partial resolution nearly 100%
67% had concomitant anakinra
@RheumNow ##EULAR2026 #EULARBest https://t.co/sGm43C3LfH
Links:
Bella Mehta @bella_mehta ( View Tweet)
Lung US for RA-ILD screening
Comparison with diagnostic scores
147 RA pts (68 ILD on HRCT)
Asymptomatic cohort
Sens 95.4% Spe 77.7%
Risk scores alone performed poorly.
Combining US + risk scores boosted sensitivity to 100% → promising low-cost screening tool alongside HRCT. https://t.co/7C4zClaxry
Aurelie Najm @AurelieRheumo ( View Tweet)
Can AI read 20 years of RA X-rays?
And how much faster/better than us?
20 years ESPOIR cohort 7500+ joints
RADAR algorithm
94–95% accuracy compared with expert readers
99% spe 93% sens
#OP0344 #EULAR2026 @RheumNow https://t.co/8hFHCY4SaY
Aurelie Najm @AurelieRheumo ( View Tweet)
DAY 3 Recap: EULAR 2026 Highlights https://t.co/ugmvSBoOzO
Links:
Dr. John Cush @RheumNow ( View Tweet)
Diet as a DMARD? The Evidence Is Still Hard to Swallow
Dietary interventions are rarely taken as seriously as pharmacological therapies in rheumatology. Yet patients ask about them constantly, and an increasing number of studies suggest that nutrition may influence disease https://t.co/BLrr3CNZMg
Dr. John Cush @RheumNow ( View Tweet)
Can AI spot RA inflammation from a thermal hand scan?
Cohort 100 RA pts
AI model analysing thermal images detected US PD+ wrist inflammation AUC 0.87
Main features wrist temperature & heat-pattern
With all due validation could this be the next mass screening tool for RA? https://t.co/2AzXj5yQJI
Aurelie Najm @AurelieRheumo ( View Tweet)
No big surprise here, deucravacitinib does as well without MTX
Pooled analysis of 52wk data of POETYK PSA
Same ACR20/50/70 and MDA response profiles also similar safety profiles
#POS0288 #EULAR2026 @RheumNow https://t.co/XqLfZstRuS
Aurelie Najm @AurelieRheumo ( View Tweet)
A biomarker for CV disease in RA?
Anti-CXCR3 antibodies asso w/ atherosclerosis
Confirmed in a validation cohort
Adding Ab profile to the mSCORE increases
AUC from 0.6 to 0.9
Sens from 30 to 69%
How does it compare with other ways of detecting atherosclerosis?
#POS0899 https://t.co/O7bsLrVyzo
Links:
Aurelie Najm @AurelieRheumo ( View Tweet)
How to treat #RA-#ILD
Similar to #IPF
Occurs older men esp
Smoking risk
Vaccines
Etc
Philippe Dieude
#HOT #EULAR2026 @RheumNow https://t.co/F4h9daSLhF
Janet Pope @Janetbirdope ( View Tweet)
Which b/tsDMARDs are effective in #axSpA? Stratified by extramusculoskeletal manifestations
Check out the latest update of the treatment heatmap 🔥
By Astrid van Tubergen
At axial and peripheral SpA at a crossroads session
#EULAR2026
@RheumNow https://t.co/uTxEJqbDBm
Nelly ZIADE 🍀 @Nellziade ( View Tweet)
Controversial
#Rheumatoid #arthritis disease activity
May not affect #ILD
BUT affects #mortality
level evidence +/-
PHillippe Dieude said
#Rx from RCTs
#IS
Ex #rituximab
#antifibrotics
#nintedanib
#nerandomilast
HOw to Treat RA-ILD June 5
#EULAR2026 @RheumNow @eular_ARD https://t.co/R60nX6XzL8
Links:
Janet Pope @Janetbirdope ( View Tweet)
Which b/tsDMARDs are NOT effective in #axSpA?
Check out the latest update of the treatment heatmap 🔥
By Astrid van Tubergen
At axial and peripheral SpA at a crossroads session
#EULAR2026
@RheumNow https://t.co/hqfLAYeri3
Nelly ZIADE 🍀 @Nellziade ( View Tweet)
Key messages in the tx of ax/p-SpA:
>csDMARDs only effective in pSpA
>consider individualized treatment for bDMARDs and JAKis
>Cycling TNFi equally effective to switching
@RheumNow #EULAR2026 https://t.co/oeO3BxmYYo
sheila @RHEUMarampa ( View Tweet)
JAK Safety Debate Continues: Stronger VTE signal, less clear cancer signal
Few topics in rheumatology have reshaped prescribing behaviour as dramatically as the safety concerns surrounding JAK inhibitors following ORAL Surveillance and the subsequent FDA and EMA warnings. https://t.co/mvTRRL7srA
Dr. John Cush @RheumNow ( View Tweet)
Which b/tsDMARDs are effective in #axSpA?
Check out the latest update of the treatment heatmap 🔥
By Astrid van Tubergen
At axial and peripheral SpA at a crossroads session
#EULAR2026
@RheumNow https://t.co/8mj24lAOTk
Nelly ZIADE 🍀 @Nellziade ( View Tweet)
What b/ts DMARDs are effective and not effective in axSpA?
Prof. Astrid van Tubergen presents this very informative summary slide summarizing treatment in axSpA.
@RheumNow #EULAR2026 https://t.co/5udGPB1Hrr
Links:
sheila @RHEUMarampa ( View Tweet)
What is the @Official_ASAS recommended instrument for evaluating peripheral disease activity in axial and peripheral spondyloarthritis?
👉 DAPSA44
✔️Good construct validity
✔️ High discriminatory capacity
From the ASAS-Sparadise study
#EULAR2026
@RheumNow https://t.co/Jbdvpn95jE
Nelly ZIADE 🍀 @Nellziade ( View Tweet)
From the Blog
Podcasts
EULAR 2026 Daily Podcast Day 2c-
EULAR 2026 Daily Podcast Day 2b
Daily Recap Day 1 + 2 EULAR 2026-
EULAR 2026 Daily Podcast Day 2a
Therapeutic Updates
Psoriatic arthritis and overweight or obesity
Sponsored by Lilly Medical Affairs
Dr. Merola presenting the results from TOGETHER‑PsA, a phase 3b trial evaluating the concomitant use of an IL‑17A antagonist and an incretin receptor agonist in adults with psoriatic arthritis and overweight or obesity.
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
